Work

Postoperative pneumonia in patients with non-small cell lung cancer undergoing thoracoscopic surgery: What should we care about?

Year: 2025

Type: article

Abstract: Background: The prevention of postoperative pneumonia in patients with non-small cell lung cancer (NSCLC) undergoing thoracoscopic surgery holds significant clinical importance. This study aimed to evaluate the status quo and influencing factors of postoperative pneumonia in patients with NSCLC. Methods: Patients with NSCLC undergoing thoracoscopic surgery at our hospital from January 2023 to October 2024 were included. The characteristics of patients with and without postoperative pneumonia were analyzed. A logistic regression model was employed to analyze the influencing factors of postoperative pneumonia, and a corresponding predictive model was constructed. The predictive performance of the model was evaluated using receiver operating characteristic (ROC) curve analysis. Results: A total of 226 patients with NSCLC were included, the incidence of postoperative pneumonia in patients with NSCLC was 31.86%. Correlation analyses showed that age(r=0.570), scope of the surgical procedure(r=0.618), COPD(r=0.562), history of smoking(r=0.516) and hypoproteinemia(r=0.587) were associated with the occurrence of postoperative pneumonia. Logistic regression analysis revealed that age (OR=2.146, 95%CI: 1.439~3.045), scope of the surgical procedure (OR=3.009, 95%CI: 2.813~3.543), COPD (OR=2.312, 95%CI: 1.605~3.008), history of smoking (OR=2.445, 95%CI: 2.117~2.821) and hypoproteinemia(OR=1.997, 95%CI: 1.533~2.580) were the independent influencing factors of postoperative pneumonia in patient with NSCLC. The area under the ROC curve (AUC) was 0.830. Conclusion: The incidence of postoperative pneumonia in patients with NSCLC is relatively high and is influenced by a multitude of factors. The postoperative pneumonia risk prediction model developed in this study has demonstrated promising predictive performance. However, given the single-center design and limited sample size, additional clinical validation is necessary to confirm its practical applicability and reliability in real-world clinical settings.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2025.1564042

Authors: Jinzhi You, Dandan Chen, Xiang Liu, Hailing Zhang, Zhongfeng Zheng

Institutions: Xuzhou Medical College, Nanjing Medical University

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801